Symbio
Private Company
Funding information not available
Overview
Symbio is a privately held, specialized contract research organization (CRO) that offers comprehensive clinical trial services exclusively for dermatology, aesthetics, gastroenterology, and inflammation. With a claimed history of over 20 years of collective experience, the company supports over 650 trials across 85+ indications and cites involvement in 70+ FDA approvals. Its business model is entirely service-based, providing functional and full-service CRO solutions, including a unique in-house topical formulation development subsidiary, to biopharma and medical device sponsors.
Technology Platform
Integrated suite of in-house clinical trial services with specialized therapeutic expertise in dermatology, aesthetics, gastroenterology, and inflammation. Includes a subsidiary (Dow Development Laboratories, LLC) for turnkey topical formulation development.
Opportunities
Risk Factors
Competitive Landscape
Symbio competes in the crowded CRO market, differentiated by its narrow therapeutic focus. It competes against large, diversified CROs (e.g., IQVIA, PPD) on specialization and against other boutique CROs on the breadth of its integrated in-house services and its unique topical formulation development capability.